SLC5A2 and heart failure: However, given the preclinical successes of the newer antihyperglycemicagents of the sodium glucose cotransporter-2 (SGLT2) inhibitor [293] andglucagon-like peptide-1 (GLP1) receptor agonist [294] on the treatment ofexperimental PH and in human trials of heart failure with PH in general, it isexpected that these drugs will soon advance to clinical trials in PAH.